natgillin/translations-raw huggingface dataset:
There is no relevant use of MIRAPEXIN prolonged-release tablets in the paediatric population for the indication of Parkinson's Disease. 
Nema relevantne primjene MIRAPEXIN tableta s produljenim oslobađanjem u pedijatrijskoj populaciji za indikaciju Parkinsonove bolesti.
Cartons containing 3 or 10 blister strips (30 or 100 tablets). 
Kutije sadrže 3 ili 10 blistera (30 ili 100 tableta)
Tell your doctor if you or your family/carer notices that you are developing mania (agitation, feeling elated or over-excited) or delirium (decreased awareness, confusion, loss of reality). 
Obavijestite liječnika ako Vi ili Vaša obitelj / skrbnik primijetite razvoj manije (uznemirenost, osjećaj ushita ili pretjeranog uzbuđenja) ili delirija (poremećaj svijesti, konfuzija, gubitak osjećaja za stvarnost).
In advanced Parkinson's disease, pramipexole doses higher than 1.1 mg of base (1.5 mg of salt) per day can be useful in patients where a reduction of the levodopa therapy is intended. 
U uznapredovaloj Parkinsonovoj bolesti, dnevne doze više od 1,1 mg baze (1,5 mg soli) mogu biti korisne kod bolesnika kojima se namjerava sniziti doza levodope.
Store in the original package to protect the tablets from light. 
Čuvati u originalnom pakiranju radi zaštite tableta od svjetlosti.
Tell your doctor if you or your family/carer notices that you are developing mania (agitation, feeling elated or over-excited) or delirium (decreased awareness, confusion or loss of reality). 
Obavijestite liječnika ako Vi ili Vaša obitelj / skrbnik primijetite razvoj manije (uznemirenost, osjećaj ushita ili pretjeranog uzbuđenja) ili delirija (poremećaj svijesti, konfuzija ili gubitak osjećaja za stvarnost).
Parkinson's disease and are also taking levodopa, you might develop dyskinesia during the up titration of MIRAPEXIN. 
Parkinsonovu bolest te također uzimate levodopu, može doći do razvoja diskinezije tijekom povećavanja doze MIRAPEXINA.
During the first week, the usual dose is 1 tablet MIRAPEXIN 0.088 mg three times a day (equivalent to 0.264 mg daily): 
Tijekom prvog tjedna, uobičajena doza je 1 tableta MIRAPEXINA 0,088 mg tri puta dnevno (što odgovara 0,264 mg dnevno):
If you have moderate kidney disease, the usual starting dose is 1 tablet MIRAPEXIN 0.088 mg twice a day. 
Ako imate umjerenu bolest bubrega, uobičajena početna doza je 1 tableta MIRAPEXINA 0,088 mg dvaput dnevno.
Parkinson's disease The daily dose is to be taken divided into 3 equal doses. 
Ukupna dnevna doza se uzima podijeljena u 3 jednake doze.
What MIRAPEXIN looks like and contents of the pack MIRAPEXIN 0.26 mg and 0.52 mg prolonged-release tablets are white to off-white, of round shape, and have bevelled edges. 
Kako MIRAPEXIN izgleda i sadržaj pakiranja MIRAPEXIN 0,26 mg i 0,52 mg tablete s produljenim oslobađanjem su bijele do gotovo bijele boje, okruglog oblika, te imaju kose rubove.
During the first week, the usual dose is 1 tablet MIRAPEXIN 0.088 mg once a day (equivalent to 0.088 mg daily): 
Tijekom prvog tjedna, uobičajena doza je 1 tableta MIRAPEXIN 0,088 mg jedanput dnevno (što odgovara 0,088 mg dnevno):
MIRAPEXIN is not recommended for use in children and adolescents below 18 years since the efficacy and safety has not been established in this population. 
Primjena MIRAPEXINA se ne preporučuje u djece i adolescenata u dobi do 18 godina jer njegova sigurnost i djelotvornost nije ustanovljena za ovu populaciju.
In patients with a creatinine clearance less than 20 ml/min, the daily dose of MIRAPEXIN should be administered in a single dose, starting at 0.088 mg of base (0.125 mg of salt) daily. 
U bolesnika s klirensom kreatinina manjim od 20 ml/min, MIRAPEXIN je potrebno primijeniti u jednokratnoj dozi, počevši od 0,088 mg baze (0,125 mg soli) dnevno.
Based on the analysis of pooled placebo-controlled trials, comprising a total of 1,923 patients on pramipexole and 1,354 patients on placebo, adverse drug reactions were frequently reported for both groups. 
Na temelju analize zbirnih podataka iz placebom kontroliranih ispitivanja, koja su obuhvatila 1923 bolesnika na pramipeksolu i 1354 bolesnika na placebu, nuspojave su se često prijavljivale za obje grupe.
A precise frequency estimation is not possible as the side effect did not occur in a clinical trial database of 1,395 patients with Restless Legs Syndrome treated with pramipexole 
Precizna procjena učestalosti nije moguća, s obzirom na to da se nuspojava nije pojavila u bazi podataka kliničkog ispitivanja u 1395 bolesnika sa sindromom nemirnih nogu liječenih pramipeksolom.
How to take MIRAPEXIN 
Kako uzimati MIRAPEXIN
Co-administration of antipsychotic medicinal products with pramipexole should be avoided (see section 4.5). 
Treba izbjegavati istodobnu primjenu antipsihotičnih lijekova i pramipeksola (vidjeti dio 4.5).
Take care if you are taking the following medicines: - cimetidine (to treat excess stomach acid and stomach ulcers) - amantadine (which can be used to treat Parkinson's disease) - mexiletine (to treat irregular heartbeats, a condition known as ventricular arrhythmia) - zidovudine (which can be used to treat the acquired immune deficiency syndrome (AIDS), a disease of the human immune system) - cisplatin (to treat various types of cancers) - quinine (which can be used for the prevention of painful night-time leg cramps and for the treatment of a type of malaria known as falciparum malaria (malignant malaria)) - procainamide (to treat irregular heart beat) 
Budite na oprezu ako uzimate sljedeće lijekove: - cimetidin (za liječenje prekomjernog stvaranja želučane kiseline i želučanih ulkusa) - amantadin (koji se primjenjuje u liječenju Parkinsonove bolesti) - meksiletin (za liječenje nepravilnih otkucaja srca, stanja koje se naziva ventrikularna aritmija) - zidovudin (koji se može primjenjivati u liječenju stečenog sindroma imunodeficijencije (SIDA),
Very common: - Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs) - Sleepiness - Dizziness - Nausea (sickness) 
Vrlo često: - diskinezija (npr. abnormalni, nekontrolirani pokreti udova) - pospanost - omaglica - mučnina
In severe kidney disease, the usual starting dose is just 1 tablet MIRAPEXIN 0.088 mg a day. 
Kod teške bolesti bubrega, uobičajena početna doza je samo 1 tableta MIRAPEXIN 0,088 mg dnevno.
Each tablet contains 0.088 mg, 0.18 mg, 0.35 mg, or 0.7 mg pramipexole as 0.125 mg, 0.25 mg, 0.5 mg, or 1 mg pramipexole dihydrochloride monohydrate, respectively. 
Jedna tableta sadrži: 0,088 mg; 0,18 mg; 0,35 mg; ili 0,7 mg pramipeksola u obliku 0,125 mg; 0,25 mg; 0,5 mg; ili 1 mg pramipeksoldiklorid hidrata, po istom redoslijedu.
Each tablet contains 0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg, or 3.15 mg pramipexole as 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, or 4.5 mg pramipexole dihydrochloride monohydrate, respectively. 
Jedna tableta sadrži 0,26 mg; 0,52 mg; 1,05 mg; 1,57 mg; 2,1 mg; 2,62 mg; ili 3,15 mg pramipeksola u obliku 0,375 mg; 0,75 mg; 1,5 mg; 2,25 mg; 3 mg; 3,75 mg; ili 4,5 mg pramipeksoldiklorid hidrata, po istom redoslijedu.
For the side effects marked with * a precise frequency estimation is not possible, since these side effects were not observed in clinical studies among 2,762 patients treated with pramipexole. 
Za nuspojave koje su označene sa * nije moguća precizna ocjena učestalosti, s obzirom da ove nuspojave nisu primijećene u kliničkim ispitivanjima na 2762 bolesnika liječenih pramipeksolom.
Ascending dose schedule of MIRAPEXIN prolonged-release tablets Week Daily dose (mg) Number of tablets One MIRAPEXIN 0.26 mg prolonged-release tablet. 
Režim doziranja MIRAPEXIN tableta s produljenim oslobađanjem Tjedan Dnevna doza (mg) Broj tableta Jedna MIRAPEXIN 0,26 mg tableta s produljenim oslobađanjem
MIRAPEXIN 0.7 mg tablets are white, of round shape, and flat. 
MIRAPEXIN 0,7 mg tablete su bijele, okruglog oblika, plosnate.
Reduction of the pramipexole dose should be considered when these medicinal products are administered concomitantly with MIRAPEXIN. 
Potrebno je razmotriti mogućnost sniženja doze pramipeksola u slučaju primjene navedenih lijekova u kombinaciji s MIRAPEXINOM.
Dose Schedule of MIRAPEXIN Titration Step Once Daily Evening Dose 
Raspored doziranja MIRAPEXINA Titracijski korak Večernja doza jedanput dnevno (mg baze)
Boehringer Ingelheim International GmbH D-55216 Ingelheim am Rhein Germany 
Boehringer Ingelheim International GmbH D-55216 Ingelheim am Rhein Njemačka
If you are switching from MIRAPEXIN (immediate release) tablets Your doctor will base your dose of MIRAPEXIN prolonged-release tablets on the dose of MIRAPEXIN (immediate release) tablets you were taking. 
Liječnik će započeti s dozom MIRAPEXIN tableta s produljenim oslobađanjem adekvatno Vašoj dozi MIRAPEXIN tableta (s trenutnim oslobađanjem) koju ste uzimali.
Boehringer Ingelheim Pharma GmbH & Co. KG D-55216 Ingelheim am Rhein Germany 
Boehringer Ingelheim Pharma GmbH & Co.KG D-55216 Ingelheim am Rhein Njemačka
1 tablet MIRAPEXIN 0.35 mg and 1 tablet MIRAPEXIN 0.18 mg OR 
1 tableta MIRAPEXIN 0,35 mg i 1 tableta MIRAPEXIN 0,18 mg ILI
A lower maintenance dose of one MIRAPEXIN 0.26 mg prolonged-release tablet a day is also possible. 
Također je moguća niža doza održavanja od jedne MIRAPEXIN 0,26 mg tablete s produljenim oslobađanjem dnevno.
1 tablet MIRAPEXIN 0.7 mg and 1 tablet MIRAPEXIN 0.35 mg three times a day 
1 tableta MIRAPEXIN 0,7 mg i 1 tableta MIRAPEXIN 0,35 mg tri puta dnevno
MIRAPEXIN 0.18 mg tablets and MIRAPEXIN 0.35 mg tablets are white, of oval shape, and flat. 
MIRAPEXIN 0,18 mg tablete i MIRAPEXIN 0,35 mg tablete su bijele, ovalnog oblika, plosnate.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 23 February 1998 
DATUM PRVOG ODOBRENJA / DATUM OBNOVE ODOBRENJA
Common: - Changes in sleep pattern, such as sleeplessness (insomnia) and sleepiness - Tiredness (fatigue) - Headache - Abnormal dreams - Constipation - Dizziness - Vomiting (being sick) 
Često: - promjene u obrascu spavanja, kao što su nesanica i pospanost - umor - glavobolja - neobični snovi
If necessary, your doctor may increase your dose up to a maximum of 3.15 mg of pramipexole a day. 
Ako je potrebno, liječnik će povisiti dozu tableta do maksimalno 3,15 mg pramipeksola dnevno.
Uncommon: - Urge to behave in an unusual way* - Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)* - Inappropriate antidiuretic hormone secretion* - Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs) - Hyperkinesia (increased movements and inability to keep still)* - Paranoia (e.g. excessive fear for one's own well-being)* - Delusion* - Amnesia (memory disturbance)* - Hallucinations (seeing, hearing or feeling things that are not there) - Confusion - Excessive daytime sleepiness and suddenly falling asleep - Weight increase - Hypotension (low blood pressure) - Excess of fluid, usually in the legs (peripheral oedema) - Allergic reactions (e.g. rash, itching, hypersensitivity) - Fainting - Restlessness - Visual impairment - Weight loss including decreased appetite - Dyspnoea (difficulties to breathe) - Hiccups - Pneumonia (infection of the lungs)* - Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include: 
Manje često: - potreba za neuobičajenim ponašanjem* - zatajenje srca (problemi sa srcem koji mogu izazvati nedostatak zraka i otečenost gležnjeva)* - neodgovarajuće lučenje antidiuretskog hormona* - diskinezija (npr. abnormalni, nekontrolirani pokreti udova) - hiperkinezija (učestali pokreti i nesposobnost ostajanja u mirnom položaju)* - paranoja (npr. pretjeran strah za vlastitu dobrobit)* - zablude (deluzije)* - amnezija (poremećaj pamćenja)* - halucinacije (vidjeti, čuti ili osjećati stvari koje nisu prisutne) - smetenost - prekomjerna dnevna pospanost i iznenadno usnivanje - porast tjelesne težine - hipotenzija (niski krvni tlak) - prekomjerno nakupljanje tekućine, obično u nogama (periferni edem) - alergijske reakcije (npr. osip, svrbež, preosjetljivost) - nesvjestica - nemir - poremećaj vida - gubitak težine uključujući smanjeni apetit - zaduha (otežano disanje) - štucanje - upala pluća (infekcija pluća)* - Nemogućnost odupiranja nagonu, porivu ili iskušenju za vršenje radnji koje bi mogle naškoditi
MIRAPEXIN 0.26 mg prolonged-release tablets MIRAPEXIN 0.52 mg prolonged-release tablets MIRAPEXIN 1.05 mg prolonged-release tablets MIRAPEXIN 1.57 mg prolonged-release tablets MIRAPEXIN 2.1 mg prolonged-release tablets MIRAPEXIN 2.62 mg prolonged-release tablets MIRAPEXIN 3.15 mg prolonged-release tablets 
MIRAPEXIN 0,26 mg tablete s produljenim oslobađanjem MIRAPEXIN 0,52 mg tablete s produljenim oslobađanjem MIRAPEXIN 1,05 mg tablete s produljenim oslobađanjem MIRAPEXIN 1,57 mg tablete s produljenim oslobađanjem MIRAPEXIN 2,1 mg tablete s produljenim oslobađanjem MIRAPEXIN 2,62 mg tablete s produljenim oslobađanjem MIRAPEXIN 3,15 mg tablete s produljenim oslobađanjem pramipeksol
How to store MIRAPEXIN 
Kako čuvati MIRAPEXIN
In clinical studies and post-marketing experience cardiac failure has been reported in patients with pramipexole. 
U kliničkim studijama i tijekom razdoblja nakon izdavanja odobrenja za stavljanje gotovog lijeka u promet prijavljeno je zatajenje srca kod bolesnika na pramipeksolu.
two MIRAPEXIN 0.52 mg prolonged-release tablets, OR four MIRAPEXIN 0.26 mg prolonged-release tablets. 
ILI dvije MIRAPEXIN 0,52 mg tablete s produljenim oslobađanjem ILI četiri MIRAPEXIN 0,26 tablete s produljenim oslobađanjem.
However, it should be noted that the incidence of somnolence is increased at doses higher than 1.5 mg (of salt) per day (see section 4.8). 
Međutim, potrebno je napomenuti da se incidencija somnolencije povećava pri dozama višim od 1,5 mg (soli) dnevno (vidjeti dio 4.8).
Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with MIRAPEXIN. 
Tijekom liječenja MIRAPEXINOM bolesnici moraju biti informirani o tome, te ih se mora upozoriti na povećan oprez pri upravljanju motornim vozilima ili strojevima.
Take your MIRAPEXIN (immediate release) tablets as normal the day before you switch. 
Uzmite MIRAPEXIN tablete (s trenutnim oslobađanjem) po uobičajenom rasporedu dan prije prijelaza na drugu terapiju.
How to store MIRAPEXIN Contents of the pack and other information 
Kako MIRAPEXIN izgleda i sadržaj pakiranja
MIRAPEXIN 0.088 mg tablets MIRAPEXIN 0.18 mg tablets MIRAPEXIN 0.35 mg tablets MIRAPEXIN 0.7 mg tablets Pramipexole 
MIRAPEXIN 0,088 mg tablete MIRAPEXIN 0,18 mg tablete MIRAPEXIN 0,35 mg tablete MIRAPEXIN 0,7 mg tablete pramipeksol
MIRAPEXIN 0.088 mg tablets MIRAPEXIN 0.18 mg tablets MIRAPEXIN 0.35 mg tablets MIRAPEXIN 0.7 mg tablets 
MIRAPEXIN 0,088 mg tablete MIRAPEXIN 0,18 mg tablete MIRAPEXIN 0,35 mg tablete MIRAPEXIN 0,7 mg tablete
Tourette Disorder 
Touretteov sindrom
Common: - Urge to behave in an unusual way - Hallucinations (seeing, hearing or feeling things that are not there) - Confusion - Tiredness (fatigue) - Sleeplessness (insomnia) - Excess of fluid, usually in the legs (peripheral oedema) - Headache - Hypotension (low blood pressure) - Abnormal dreams - Constipation - Visual impairment - Vomiting (being sick) - Weight loss including decreased appetite 
Često: - potreba za neuobičajenim ponašanjem - halucinacije (vidjeti, čuti ili osjećati stvari koje nisu prisutne) - smetenost - umor - nesanica - prekomjerna količina tekućine, obično u nogama (periferni edem) - glavobolja - hipotenzija (niski krvni tlak) - neuobičajeni snovi - zatvor - poremećaji vida - povraćanje - gubitak težine uključujući smanjen apetit
Uncommon (≥1/1,000 to 
Manje često (≥1/1000 i < 1/100)
This side effect has been observed in post-marketing experience. 
Ova je nuspojava primijećena u razdoblju nakon stavljanja lijeka u promet.
sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS). 
tjeskoba, umor, znojenje ili bol (što se naziva sindromom ustezanja od agonista dopamina).
Uncommon: - Paranoia (e.g. excessive fear for one's own well-being) - Delusion - Excessive daytime sleepiness and suddenly falling asleep - Amnesia (memory disturbance) - Hyperkinesia (increased movements and inability to keep still) - Weight increase - Allergic reactions (e.g. rash, itching, hypersensitivity) - Fainting - Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)* - Inappropriate antidiuretic hormone secretion* - Restlessness - Dyspnoea (difficulties to breathe) - Hiccups - Pneumonia (infection of the lungs) - Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include: 
Manje često: - paranoja (npr. pretjeran strah za vlastitu dobrobit) - zablude (deluzije) - prekomjerna dnevna pospanost i iznenadno usnivanje - amnezija (poremećaj pamćenja) - hiperkinezija (učestali pokreti i nesposobnost ostajanja u mirnom položaju) - porast tjelesne težine - alergijske reakcije (npr. osip, svrbež, preosjetljivost) - nesvjestica - zatajenje srca (problemi sa srcem koji mogu izazvati nedostatak zraka ili otečenost gležnjeva)*
1 tablet MIRAPEXIN 0.35 mg 
1 tableta MIRAPEXIN 0,35 mg
Doses should be increased gradually from a starting dose of 0.26 mg of base (0.375 mg of salt) per day and then increased every 5-7 days. 
Dozu je potrebno postupno povisivati od početne doze 0,26 mg baze (0,375 mg soli) dnevno, svakih 5-7 dana.
MARKETING AUTHORISATION NUMBER(S) MIRAPEXIN 0.26 mg prolonged-release tablets EU/1/97/051/013-015 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET MIRAPEXIN 0,26 mg tablete s produljenim oslobađanjem EU/1/97/051/013-015
MIRAPEXIN 2.62 mg prolonged-release tablets EU/1/97/051/031-033 
MIRAPEXIN 2,62 mg tablete s produljenim oslobađanjem EU/1/97/051/031-033
MIRAPEXIN 0.26 mg prolonged-release tablets Each prolonged-release tablet contains 0.375 mg pramipexole dihydrochloride monohydrate equivalent to 0.26 mg pramipexole. 
MIRAPEXIN 0,26 mg tablete s produljenim oslobađanjem Jedna tableta s produljenim oslobađanjem sadrži 0,375 mg pramipeksoldiklorid hidrata, što odgovara 0,26 mg pramipeksola.
MIRAPEXIN 0.35 mg tablets EU/1/97/051/011-012 
MIRAPEXIN 0,35 mg tablete EU/1/97/051/011-012
Common: - Urge to behave in an unusual way - Hallucinations (seeing, hearing or feeling things that are not there) - Confusion - Tiredness (fatigue) - Sleeplessness (insomnia) - Excess of fluid, usually in the legs (peripheral oedema) - Headache - Hypotension (low blood pressure) - Abnormal dreams - Constipation - Visual impairment 
Često: - potreba za neuobičajenim ponašanjem - halucinacije (vidjeti, čuti ili osjećati stvari koje nisu prisutne) - smetenost - umor - nesanica - prekomjerna količina tekućine, obično u nogama (periferni edem) - glavobolja
Doses should be increased gradually from a starting dose of 0.264 mg of base (0.375 mg of salt) per day and then increased every 5-7 days. 
Dozu je potrebno postupno povisivati od početne doze 0,264 mg baze (0,375 mg soli) dnevno, svakih 5-7 dana.
Very common may affect more than 1 in 10 people Common may affect up to 1 in 10 people 
Ocjena ovih nuspojava zasniva se na sljedećim učestalostima: Vrlo često mogu se javiti u više od 1 na 10 osoba
MIRAPEXIN 0.52 mg prolonged-release tablets EU/1/97/051/016-018 
MIRAPEXIN 0,52 mg tablete s produljenim oslobađanjem EU/1/97/051/016-018
1 tablet MIRAPEXIN 0.35 mg three times a day OR 
1 tableta MIRAPEXINA 0,35 mg tri puta dnevno ILI
1 tablet MIRAPEXIN 0.088 mg three times a day 
1 tableta MIRAPEXIN 0,088 mg tri puta dnevno
MIRAPEXIN 0.088 mg tablets EU/1/97/051/001-002 
MIRAPEXIN 0,088 mg tablete EU/1/97/051/001-002
MIRAPEXIN 0.7 mg tablets EU/1/97/051/005-006 
MIRAPEXIN 0,7 mg tablete EU/1/97/051/005-006
- Vomiting (being sick) - Weight loss including decreased appetite 
- hipotenzija (niski krvni tlak) - neuobičajeni snovi - zatvor - poremećaji vida - povraćanje (osjećaj mučnine) - gubitak težine uključujući smanjen apetit
Restless Legs Syndrome, most common adverse reactions The most commonly (≥ 5%) reported adverse drug reactions in patients with Restless Legs Syndrome treated with pramipexole were nausea, headache, dizziness and fatigue. 
Najčešće (≥5%) prijavljene nuspojave u bolesnika sa sindromom nemirnih nogu, u liječenju pramipeksolom bile su mučnina, glavobolja, omaglica i umor.
2 tablets MIRAPEXIN 0.18 mg three times a day 
2 tablete MIRAPEXINA 0,18 mg tri puta dnevno
Nervous system disorders headache dizziness somnolance sudden onset of sleep syncope dyskinesia amnesia hyperkinesia 
Poremećaji živčanog sustava glavobolja omaglica somnolencija epizode iznenadnog usnivanja sinkopa diskinezija amnezija hiperkinezija
MIRAPEXIN 0.088 mg tablets 
MIRAPEXIN 0,088 mg tablete
MIRAPEXIN 0.18 mg tablets EU/1/97/051/003-004 
MIRAPEXIN 0,18 mg tablete EU/1/97/051/003-004
MIRAPEXIN 0.35 mg tablets 
MIRAPEXIN 0,35 mg tablete
2 tablets MIRAPEXIN 0.088 mg three times a day 
2 tablete MIRAPEXINA 0,088 mg tri puta dnevno
1 tablet MIRAPEXIN 0.18 mg three times a day OR 
1 tableta MIRAPEXINA 0,18 mg tri puta dnevno ILI
MIRAPEXIN 0.7 mg tablets 
MIRAPEXIN 0,7 mg tablete
Each prolonged-release tablet contains 1.5 mg pramipexole dihydrochloride monohydrate equivalent to 1.05 mg pramipexole. 
Jedna tableta s produljenim oslobađanjem sadrži 1,5 mg pramipeksoldiklorid hidrata što odgovara 1,05 mg pramipeksola.
MIRAPEXIN 3.15 mg prolonged-release tablets EU/1/97/051/025-027 
MIRAPEXIN 3,15 mg tablete s produljenim oslobađanjem EU/1/97/051/025-027
3 tablets MIRAPEXIN 0.18 mg 
3 tablete MIRAPEXIN 0,18 mg
INFORMATION IN BRAILLE MIRAPEXIN 2.62 mg prolonged-release tablets 
16. PODACI NA BRAILLEOVOM PISMU MIRAPEXIN 2,62 mg tablete s produljenim oslobađanjem
MIRAPEXIN 2.62 mg prolonged-release tablets 
MIRAPEXIN 2,62 mg tablete s produljenim oslobađanjem
MIRAPEXIN with food, drink and alcohol You should be cautious while drinking alcohol during treatment with MIRAPEXIN. 
MIRAPEXIN s hranom, pićem i alkoholom
MIRAPEXIN 0.18 mg tablets 
MIRAPEXIN 0,18 mg tablete
MIRAPEXIN 1.05 mg prolonged-release tablets EU/1/97/051/019-021 
MIRAPEXIN 1,05 mg tablete s produljenim oslobađanjem EU/1/97/051/019-021
MIRAPEXIN 1.57 mg prolonged-release tablets EU/1/97/051/028-030 
MIRAPEXIN 1,57 mg tablete s produljenim oslobađanjem EU/1/97/051/028-030
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 0.125 mg pramipexole dihydrochloride monohydrate equivalent to 0.088 mg pramipexole. 
NAVOĐENJE DJELATNE(IH) TVARI Jedna tableta sadrži 0,125 mg pramipeksoldiklorid hidrata što odgovara 0,088 mg pramipeksola.
MIRAPEXIN 2.1 mg prolonged-release tablets EU/1/97/051/022-024 
MIRAPEXIN 2,1 mg tablete s produljenim oslobađanjem EU/1/97/051/022-024
Pramipexole should be tapered off at a rate of 0.54 mg of base (0.75 mg of salt) per day until the daily dose has been reduced to 0.54 mg of base (0.75 mg of salt). 
Stoga je potrebno postupno smanjivati dozu pramipeksola za 0,54 mg baze (0,75 mg soli) dnevno, sve dok se ukupna dnevna doza ne snizi na 0,54 mg baze (0,75 mg soli).
MIRAPEXIN 3.15 mg prolonged-release tablets 
MIRAPEXIN 3,15 mg tablete s produljenim oslobađanjem
INFORMATION IN BRAILLE MIRAPEXIN 0.35 mg 
16. PODACI NA BRAILLEOVOM PISMU MIRAPEXIN 0,35 mg
Each tablet contains 0.125 mg pramipexole dihydrochloride monohydrate equivalent to 0.088 mg pramipexole. 
Jedna tableta sadrži 0,125 mg pramipeksoldiklorid hidrata, što odgovara 0,088 mg pramipeksola.
2 tablets MIRAPEXIN 0.18 mg 
2 tablete MIRAPEXIN 0,18 mg
NAME OF THE MEDICINAL PRODUCT MIRAPEXIN 0.088 mg tablets Pramipexole 
NAZIV LIJEKA MIRAPEXIN 0,088 mg tablete pramipeksol
INFORMATION IN BRAILLE MIRAPEXIN 0.088 mg 
16. PODACI NA BRAILLEOVOM PISMU MIRAPEXIN 0,088 mg
MIRAPEXIN 0.52 mg prolonged-release tablets 
MIRAPEXIN 0,52 mg tablete s produljenim oslobađanjem
MIRAPEXIN 0.26 mg prolonged-release tablets 
MIRAPEXIN 0,26 mg tablete s produljenim oslobađanjem
INFORMATION IN BRAILLE MIRAPEXIN 0.26 mg prolonged-release tablets 
16. PODACI NA BRAILLEOVOM PISMU MIRAPEXIN 0,26 mg tablete s produljenim oslobađanjem
INFORMATION IN BRAILLE MIRAPEXIN 1.57 mg prolonged-release tablets 
16. PODACI NA BRAILLEOVOM PISMU MIRAPEXIN 1,57 mg tablete s produljenim oslobađanjem
MIRAPEXIN 1.57 mg prolonged-release tablets 
MIRAPEXIN 1,57 mg tablete s produljenim oslobađanjem